CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-21 | Mehta Vimal CEO and President | Option exercise | +30,000 | $0.41 | $12K | 45,894 |
| 2023-03-21 | Mehta Vimal CEO and President | Sale | −29,100 | $19.70 | $573K | 16,794 |
| 2023-03-21 | Mehta Vimal CEO and President | Sale | −900 | $20.15 | $18K | 15,894 |
| 2023-03-21 | Mehta Vimal CEO and President | Option exercise · Stock Option (Right to Buy) | −30,000 | 354,000 | ||
| 2023-03-20 | Mehta Vimal CEO and President | Option exercise | +30,000 | $0.41 | $12K | 50,394 |
| 2023-03-20 | Mehta Vimal CEO and President | Sale | −24,667 | $18.20 | $449K | 25,727 |
| 2023-03-20 | Mehta Vimal CEO and President | Sale | −5,333 | $18.86 | $101K | 20,394 |
| 2023-03-20 | Mehta Vimal CEO and President | Sale | −3,896 | $18.22 | $71K | 16,498 |
| 2023-03-20 | Mehta Vimal CEO and President | Sale | −604 | $18.88 | $11K | 15,894 |
| 2023-03-20 | Mehta Vimal CEO and President | Option exercise · Stock Option (Right to Buy) | −30,000 | 384,000 | ||
| 2023-03-15 | Steinhart Richard I Chief Financial Officer | Sale | −2,084 | $19.50 | $41K | 1,500 |
| 2023-03-15 | Steinhart Richard I Chief Financial Officer | Grant or award · Restricted Stock Units | +9,000 | 9,000 | ||
| 2023-03-15 | Steinhart Richard I Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2023-03-15 | Yocca Frank Chief Scientific Officer | Sale | −985 | $19.69 | $19K | 9,496 |
| 2023-03-15 | Yocca Frank Chief Scientific Officer | Grant or award · Restricted Stock Units | +9,000 | 9,000 | ||
| 2023-03-15 | Yocca Frank Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2023-03-15 | Mehta Vimal CEO and President | Grant or award · Restricted Stock Units | +56,000 | 56,000 | ||
| 2023-03-15 | Mehta Vimal CEO and President | Grant or award · Stock Option (Right to Buy) | +168,000 | 168,000 | ||
| 2023-03-15 | O'Neill Vincent Chief Medical Officer | Sale | −845 | $19.70 | $17K | 1,239 |
| 2023-03-15 | O'Neill Vincent Chief Medical Officer | Grant or award · Restricted Stock Units | +9,000 | 9,000 |
Page 19 of 27 · 521 trades